RxDoctor Payments DataLook up a doctor →

David Farrow, NP

Gerontology · Phoenix, AZNPI 1417518564

Payments from drug & device makers

$8,815in general payments, 2019–2025

Across 514 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Merck$607
  • AstraZeneca$606
  • Amgen$455
  • Lilly USA, LLC$434
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,815 in reported general payments places this provider in the 90th percentile of 99 gerontology providers in Arizona.

See all gerontology providers in Arizona

Medicare billing

Part B allowed, 2024
$74,043
Medicare patients
248
Services billed
1,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$19,990
Lagevrio (Eua)Molnupiravir11$3,251
Venlafaxine Hcl ErVenlafaxine Hcl15$3,082
Doxycycline Monohydrate74$855
Duloxetine Hcl12$740
Albuterol Sulfate HfaAlbuterol Sulfate39$701
Atorvastatin Calcium49$478
Rosuvastatin Calcium31$425
Azelastine Hcl12$418
Omeprazole18$413
Amlodipine Besylate59$409
Levothyroxine Sodium49$401
Losartan Potassium43$365
Hydroxyzine Hcl11$322
Metformin Hcl43$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,069$19,99020 claims
MerckLagevrio (Eua)$607$3,25111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 gerontology providers in Arizona.

Other gerontology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →